Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 125 for Ovarian

Edit search filters
  1. Suppression Of Ovarian Function With Either Tamoxifen Or Exemestane Compared With Tamoxifen Alone In Treating Premenopausal Women With Hormone-Responsive Breast Cancer

    Eau Claire, WI

  2. A Study Of Rucaparib In Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ARIEL2)

    Jacksonville, FL, Rochester, MN

  3. Vaccine Therapy In Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, Or Primary Peritoneal Cavity Cancer Following Surgery And Chemotherapy

    Rochester, MN

  4. A Phase Ib Study Of Cobimetinib Administered In Combination With Niraparib, With Or Without Atezolizumab, To Patients With Advanced Platinum-Sensitive Ovarian Cancer

    Jacksonville, FL

  5. A Study To Investigate The Safety And Effectiveness Of FE 999049 In Controlled Ovarian Stimulation In Women Aged 35-42 Years Old

    Rochester, MN

  6. A Study Comparing Gemcitabine With Or Without AZD 1775 In Treating Patients With Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer

    Rochester, MN

  7. A Open Label Study Of The Efficacy And Safety Of PD0332991 A Selective Inhibitor Of The Cyclin Dependent Kinases 4 And 6 In Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency And Low P16 Expression

    Rochester, MN

  8. Veliparib With Carboplatin And Paclitaxel And As Continuation Maintenance Therapy In Subjects With Newly Diagnosed Stage III Or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

    Rochester, MN

  9. Outcomes After Secondary Cytoreductive Surgery With Or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed By Systemic Combination Chemotherapy For Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

    Rochester, MN

  10. Evaluating The Addition Of Adjuvant Chemotherapy To Ovarian Function Suppression Plus Endocrine Therapy In Premenopausal Patients With PN0-1, ER-Positive/HER2-Negative Breast Cancer And An Oncotype Recurrence Score Less Than Or Equal To 25

    Scottsdale/Phoenix, AZ, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

.

Mayo Clinic Footer